These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29166741)

  • 41. [NT5C2 expression in children with acute leukemia and its clinical significance].
    Wang Y; An X; Liu J; Zhang N; Liu Z; Liang S; Yu J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):748-53. PubMed ID: 26462774
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
    Wu J; Lu AD; Zhang LP; Zuo YX; Jia YP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):52-57. PubMed ID: 30704229
    [No Abstract]   [Full Text] [Related]  

  • 43. [A long-term follow-up study of 82 children with acute myeloid leukemia].
    Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
    [No Abstract]   [Full Text] [Related]  

  • 44. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
    Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
    Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of NCCN (2015) risk stratification on prognosis of patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Wang H; Liu HX; Wang T; Tong CR; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):44-49. PubMed ID: 28219225
    [No Abstract]   [Full Text] [Related]  

  • 47. Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker.
    Abdollahpour-Alitappeh M; Razavi-Vakhshourpour S; Abolhassani M
    Biotechnol Appl Biochem; 2018 Nov; 65(6):841-847. PubMed ID: 29972607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study on relationship between Set gene expression and clinical manifestations in bone marrow of patients with acute myelogenous leukemia].
    Liu Y; Lei T; Shi Y; Wang XY; Sun ML; Fan WX; Zhang ZN; Jiang M
    Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(9):682-687. PubMed ID: 29534404
    [No Abstract]   [Full Text] [Related]  

  • 49. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [CD34(+)CD19(+) cells with CD123 overexpression are a novel prognostic marker in Ph chromosome-positive acute lymphoblastic leukemia].
    Kong Y; Huang XJ; Hao L; Qin YZ; Jiang Q; Jiang H; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):6-10. PubMed ID: 24598641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
    He SZ; Busfield S; Ritchie DS; Hertzberg MS; Durrant S; Lewis ID; Marlton P; McLachlan AJ; Kerridge I; Bradstock KF; Kennedy G; Boyd AW; Yeadon TM; Lopez AF; Ramshaw HS; Iland H; Bamford S; Barnden M; DeWitte M; Basser R; Roberts AW
    Leuk Lymphoma; 2015 May; 56(5):1406-15. PubMed ID: 25248882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
    Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD123 Antagonistic Peptides Assembled with Nanomicelles Act as Monotherapeutics to Combat Refractory Acute Myeloid Leukemia.
    Xu S; Zhang M; Fang X; Hu X; Xing H; Yang Y; Meng J; Wen T; Liu J; Wang J; Wang C; Xu H
    ACS Appl Mater Interfaces; 2022 Aug; 14(34):38584-38593. PubMed ID: 35977045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Regulation Effect of Myeloid Leukemia No.1 Chinese Herb Medicine Prescription Combined with Chemotherapy on Th17 Cells in Bone Marrow of Patients with Acute Myeloid Leukemia].
    Zhang GL; Pan M; Wang YZ; Huang JX; Gu GS; Wang Y; Wu Q; Yao LT; Xie HR; Hu XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):328-332. PubMed ID: 33812395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34
    Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas DM; Mims A; Brooks C; Dorrance A; Walker A; Blum W; Byrd JC; Lozanski G; Vasu S; Muthusamy N
    Haematologica; 2018 Aug; 103(8):1288-1297. PubMed ID: 29773600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Nuessler V; Schmetzer H
    Eur J Haematol; 2003 Nov; 71(5):366-76. PubMed ID: 14667200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High Expression of Interleukin-3 Receptor Alpha Chain (CD123) Predicts Favorable Outcome in Pediatric B-Cell Acute Lymphoblastic Leukemia Lacking Prognosis-Defining Genomic Aberrations.
    Li Z; Chu X; Gao L; Ling J; Xiao P; Lu J; Wang Y; He H; Li J; Hu Y; Li J; Pan J; Xiao S; Hu S
    Front Oncol; 2021; 11():614420. PubMed ID: 33796456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.